Value based pricing will be introduced into the UK from January 2014 and is expected to be one of the biggest reforms to the pricing of new medicines in the UK since the Pharmaceutical Price Regulation Scheme was set up more than 50 years ago.
The Department of Health has today [6 July] published the Q1 2017 PPRS data showing that the pharmaceutical industry has paid £94 million during the first quarter (Q1) of 2017 under the 2014 Pharmaceutical Price Regulation Scheme (PPRS).
A unique partnership announced today by the pharmaceutical industry and Greater Manchester Health and Social Care Partnership will help the city region deliver its vision to be the safest and most effective place to receive medicines in the world – and cement its position on the global research and...
The Association of the British Pharmaceutical Industry (ABPI) has responded to a provisional Competition & Markets Authority (CMA) ruling that a pharmaceutical company abused its dominant position to overcharge the NHS for liothyronine tablets.
- ABPI responds to news of generic price hikes, repeating that it does not "in any way support or condone it"
Following the news that a new breast cancer medicine -Palbociclib - from Pfizer has been ruled too expensive to justify its use on the NHS by the National Institute for Health and Care Excellence (NICE), ABPI's Commercial Director, Dr Richard Torbett said it was time to review the way in which...
The Association of the British Pharmaceutical Industry (ABPI) has responded to an in-depth investigation reported in The Times today (Friday 3 June), which reported price increases in out of patent medicines.
As the consultation on the way forward for the Cancer Drugs Fund (CDF) closes, the Association of the British Pharmaceutical Industry (ABPI) urges the government to seize the opportunity and transform the way cancer medicines are assessed by the National Institute for Health and Care Excellence (...
The ABPI says industry, NICE, and NHS England need to get round the table for talks on BBC Radio 4's Today programme.
The Association of the British Pharmaceutical Industry (ABPI) has published details of payment to the Department of Health (DH) under the five-year Pharmaceutical Price Regulation Scheme (PPRS).
New figures out today from the Association of the British Pharmaceutical Industry, show that the pharmaceutical industry has contributed over £1billion to the Department of Health towards the cost of new medicines as part of the voluntary Pharmaceutical Payment Regulation Scheme (PPRS).